Trials / Recruiting
RecruitingNCT06412224
The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)
An Exploratory ITT（Investigator Initiated Study) Study to Evaluate the Preliminary Safety and Efficacy of Single Subretinal Injection of RRG001 at the End of or After Vitrectomy in Subjects With PDR
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Li Xiaorong · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to slow down disease progression, reduce postoperative complications and decrease retreatment frequency in subjects with proliferative diabetic retinopathy (PDR) by administering a single subretinal injection of RRG001 gene therapy after vitrectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RRG001 | Administered by subretinal injection. Dosage form: injection. |
Timeline
- Start date
- 2023-12-20
- Primary completion
- 2024-12-31
- Completion
- 2028-12-31
- First posted
- 2024-05-14
- Last updated
- 2024-05-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06412224. Inclusion in this directory is not an endorsement.